Contrave — Class III drug recall D-1099-2018
Terminated recall by Orexigen Therapeutics, Inc., reported 2018-08-22, distributed nationwide. Defective Container: Customer complaints of punctures in the bottle.
| Recall number | D-1099-2018 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Orexigen Therapeutics, Inc., La Jolla, CA, United States |
| Recall initiated | 2018-08-09 |
| Classified | 2018-08-16 |
| Reported by FDA | 2018-08-22 |
| Terminated | 2019-11-15 |
| Distributed | Nationwide (US) |
| Quantity | 95,296 bottles |
| Reason classes | packaging |
| NDC | 51267-0890, 51267-0890-07, 51267-0890-99 |
| Expiration dates | 2020-11-01, 2020-11-02, 2020-11-09, 2020-11-13, 2020-11-17 |
Product
Contrave (naltrexone HCl and bupropion HCl) Extended-Release Tablets, 8 mg/90 mg, 120-count bottle, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99.
Reason for recall
Defective Container: Customer complaints of punctures in the bottle.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1099-2018. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.